FIGURE 5.

Neither recombinant protein, ASN12 or SN5, appears to show toxicity in APP tg2576 or non-tg mice. A, mice were weighed prior to treatment and weekly afterward during treatment. B, survival curve of mice during the course of the experiment. C, representative Western blot of autoantibodies to human neprilysin or the human 38-amino acid LDLR domain from apoB detected at the conclusion of the 3-week experiment. Recombinant ASN12 was run on a gel, blotted to PVDF, and probed with whole blood from mice following the conclusion of the 3-week dosing. A positive control consisted of probing with an anti-human neprilysin antibody. n = 5 for each group.